GlassScriptPhysician profile
Andrew MD Woo
NPI 1750419560
$273,356.25
in general payments reported to CMS, 2019-2025
59 companies · $1,227 in 2025
The $1,227 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172K · 2020: $61K · 2021: $23K · 2022: $12K · 2023: $2,800 · 2024: $1,679 · 2025: $1,227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,630 · Education: $76.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,629.61 |
| Education | $76.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $95,076.55 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $66,335.98 | 2019-2025 | Kesimpta |
| Genentech USA, INC. | $64,410.98 | 2019-2025 | Ocrevus Zunovo |
| Emd Serono, INC. | $20,741.59 | 2019-2025 | Mavenclad |
| Celgene Corporation | $6,027.13 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $4,064.96 | 2020-2022 | |
| Novartis Pharma Ag | $3,575.00 | 2022 | |
| Abbvie INC. | $1,102.58 | 2021-2025 | Ubrelvy, Qulipta |
| Amgen INC. | $924.05 | 2019-2025 | Uplizna |
| Neurocrine Biosciences, INC. | $864.33 | 2019-2025 | Ingrezza, Ongentys |
| Lundbeck LLC | $715.14 | 2021-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $695.12 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Ucb, INC. | $673.19 | 2019-2024 | Briviact, Nayzilam |
| Amneal Pharmaceuticals LLC | $668.28 | 2019-2025 | Rytary, Crexont |
| Biogen, INC. | $660.49 | 2019-2025 | Vumerity, Tysabri, Leqembi |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Woo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.